Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review
Importance The coronavirus disease 2019 (COVID-19) pandemic, due to the novel severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide sudden …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide sudden …
[HTML][HTML] Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
M Omata, AL Cheng, N Kokudo, M Kudo, JM Lee… - Hepatology …, 2017 - Springer
There is great geographical variation in the distribution of hepatocellular carcinoma (HCC),
with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one …
with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one …
[HTML][HTML] A minimal common outcome measure set for COVID-19 clinical research
Clinical research is necessary for an effective response to an emerging infectious disease
outbreak. However, research efforts are often hastily organised and done using various …
outbreak. However, research efforts are often hastily organised and done using various …
A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for …
Background Quantification of the disease burden caused by different risks informs
prevention by providing an account of health loss different to that provided by a disease-by …
prevention by providing an account of health loss different to that provided by a disease-by …
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
Background Measuring disease and injury burden in populations requires a composite
metric that captures both premature mortality and the prevalence and severity of ill-health …
metric that captures both premature mortality and the prevalence and severity of ill-health …
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
Background Non-fatal health outcomes from diseases and injuries are a crucial
consideration in the promotion and monitoring of individual and population health. The …
consideration in the promotion and monitoring of individual and population health. The …
CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database
Abstract The Comprehensive Antibiotic Resistance Database (CARD; https://card. mcmaster.
ca) is a curated resource providing reference DNA and protein sequences, detection models …
ca) is a curated resource providing reference DNA and protein sequences, detection models …
Histone H3K27ac separates active from poised enhancers and predicts developmental state
MP Creyghton, AW Cheng… - Proceedings of the …, 2010 - National Acad Sciences
Developmental programs are controlled by transcription factors and chromatin regulators,
which maintain specific gene expression programs through epigenetic modification of the …
which maintain specific gene expression programs through epigenetic modification of the …
[HTML][HTML] Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
RS Finn, S Qin, M Ikeda, PR Galle… - … England Journal of …, 2020 - Mass Medical Soc
Background The combination of atezolizumab and bevacizumab showed encouraging
antitumor activity and safety in a phase 1b trial involving patients with unresectable …
antitumor activity and safety in a phase 1b trial involving patients with unresectable …
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
M Kudo, RS Finn, S Qin, KH Han, K Ikeda, F Piscaglia… - The Lancet, 2018 - thelancet.com
Background In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1–3, FGF receptors
1–4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed …
1–4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed …